Exploring molecular reorientations in amorphous and recrystallized felodipine at the microscopic level.
Journal
RSC advances
ISSN: 2046-2069
Titre abrégé: RSC Adv
Pays: England
ID NLM: 101581657
Informations de publication
Date de publication:
07 Oct 2020
07 Oct 2020
Historique:
received:
24
08
2020
accepted:
18
09
2020
entrez:
6
5
2022
pubmed:
8
10
2020
medline:
8
10
2020
Statut:
epublish
Résumé
Molecular reorientations were studied in amorphous, partially and fully recrystallized felodipine (calcium channel blocker, a drug from the family of 1',4-dihydropyridine) using a set of experimental methods: high-resolution solid-state nuclear magnetic resonance (NMR), relaxometry NMR and quasielastic neutron scattering (QENS). The results were compared with molecular dynamics in crystalline felodipine previously investigated [A. Pajzderska, K. Drużbicki, M. A. Gonzalez, J. Jenczyk, J. Mielcarek, J. Wąsicki, Diversity of Methyl Group Dynamics in Felodipine: a DFT Supported NMR and Neutron Scattering Study,
Identifiants
pubmed: 35521258
doi: 10.1039/d0ra07266d
pii: d0ra07266d
pmc: PMC9057141
doi:
Types de publication
Journal Article
Langues
eng
Pagination
37346-37357Informations de copyright
This journal is © The Royal Society of Chemistry.
Déclaration de conflit d'intérêts
There are no conflicts to declare.
Références
J Res Natl Inst Stand Technol. 2009 Dec 01;114(6):341-58
pubmed: 27504233
Carbohydr Res. 2014 Oct 29;398:56-62
pubmed: 25240183
Pharm Res. 2010 Sep;27(9):1869-83
pubmed: 20585845
J Pharm Sci. 2006 Dec;95(12):2692-705
pubmed: 16892209
J Pharm Sci. 2004 Jan;93(1):218-33
pubmed: 14648651
N Engl J Med. 1999 Nov 4;341(19):1447-57
pubmed: 10547409
J Pharm Sci. 2010 Jan;99(1):169-85
pubmed: 19492305
Int J Pharm. 2011 May 30;410(1-2):61-7
pubmed: 21421036
Pharm Res. 2009 Dec;26(12):2599-606
pubmed: 19806435
Pharm Res. 2005 May;22(5):797-805
pubmed: 15906176
J Phys Chem B. 2016 Oct 20;120(41):10723-10728
pubmed: 27657328
J Pharm Sci. 2000 Mar;89(3):408-16
pubmed: 10707020
Pharm Res. 2008 Apr;25(4):969-78
pubmed: 17520180
J Pharm Sci. 2007 May;96(5):960-81
pubmed: 17455355
J Pharm Sci. 2016 Sep;105(9):2527-2544
pubmed: 26886314
Mol Pharm. 2014 Nov 3;11(11):4280-90
pubmed: 25310722
Pharm Res. 2006 Oct;23(10):2306-16
pubmed: 16927182
J Pharm Sci. 2014 Sep;103(9):2635-2662
pubmed: 24715618
J Med Chem. 1986 Feb;29(2):305-7
pubmed: 3005572
Eur J Pharm Biopharm. 2000 Jul;50(1):3-12
pubmed: 10840189
J Phys Chem B. 2010 Oct 14;114(40):12792-801
pubmed: 20849135
J Pharm Sci. 2019 Jan;108(1):451-456
pubmed: 30267784
Eur J Pharm Biopharm. 2008 Oct;70(2):493-9
pubmed: 18577451
Pharm Res. 2008 Mar;25(3):647-56
pubmed: 17846870
J Pharm Sci. 2014 Dec;103(12):3950-3957
pubmed: 25351553
J Pharm Sci. 2004 Feb;93(2):384-91
pubmed: 14705195
Pharm Res. 2002 Apr;19(4):477-83
pubmed: 12033383
Pharm Res. 2010 Apr;27(4):608-18
pubmed: 20151181
Pharm Res. 2002 Apr;19(4):484-90
pubmed: 12033384